Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-18
2006-07-18
McKenzie, Thomas C. (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C560S018000
Reexamination Certificate
active
07078540
ABSTRACT:
A compound of the formula:wherein R1is an aliphatic hydrocarbon group optionally having substituent(s), an aromatic hydrocarbon group optionally having substituent(s), a heterocyclic group optionally having substituent(s), a group of the formula: OR1awherein R1ais a hydrogen atom or an aliphatic hydrocarbon group optionally having substituent(s), or a group of the formula:wherein R1band R1care the same or different and each is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituent(s), X is a methylene group, a nitrogen atom, a sulfur atom or an oxygen atom, Y is an optionally substituted methylene group or an optionally substituted nitrogen atom, ring A is a 5 to 8-membered ring optionally substituted further by 1 to 4 substituent(s) selected from (1) an aliphatic hydrocarbon group optionally having substituent(s), (2) an aromatic hydrocarbon group optionally having substituent(s), (3) a group of the formula: OR2wherein R2is a hydrogen atom, or an aliphatic hydrocarbon group optionally having substituent(s) and (4) a halogen atom, Ar is an aromatic hydrocarbon group optionally having substituent(s), a group of the formula:is a group of the formula:or the formula:m is an integer of 0 to 2, n is an integer of 1 to 3, and the sum of m and n is not more than 4, provided that when X is a methylene group, Y is an optionally substituted methylene group, and a salt thereof have an inhibitory activity on nitric oxide (NO) production and cytokine production, and are useful as an agent for the prophylaxis and/or treatment of diseases, such as cardiac disease, autoimmune disease, inflammatory disease, central nervous system disease, infectious disease, sepsis, septic shock and the like.
REFERENCES:
patent: 5378703 (1995-01-01), Dean et al.
patent: 6495604 (2002-12-01), Ichimori et al.
patent: 2003/0100580 (2003-05-01), Dhanak et al.
patent: 2004/0002425 (2004-01-01), Saitou et al.
patent: 96/31492 (1996-10-01), None
patent: 99/46242 (1999-09-01), None
Arend et al., “IL-1 Receptor Antagonist and IL-1§ Production in Human Monocytes are Regulated Differently,” Journal of Immunology, 147(2), 1530-1536 (Sep. 1, 1991).
Dinarello et al., “Blocking IL-1: Interleukin 1 Receptor Antagonist in vivo and in vitro,” Immunology Today, 12(11), 404-410 (1991).
Neuner et al., “Pentoxifylline in vivo Down-regulates the Release of IL-1§, IL-6, IL-8 and Tumour Necrosis Factor-—by Human Peripheral Blood Mononuclear Cells,” Immunology, 83(2), 262-267 (Oct. 1994).
Matsuda et al., “Establishiment of an Interleukin 6 (IL6)/B Cell Stimulatory Factor 2-Dependent Cell Line and Preparation o Anti-IL6 Monoclonal Antibodies,” European Journal of Immunology, 18, 951-956 (Jun. 1988).
Cohen et al., “CNI-1493 Inhibits Monocyte/Macrophage Tumor Necrosis Factor by Suppression of Translation Efficiency,” Proc. National Academy of Science USA, 93, 3967-3971 (Apr. 1996).
Forstermann et al., “Nitric Oxide Synthase Isozymes—Characterization, Purification, Molecular Cloning, and Functions,” Hypertension, 23(6, Part 2), 1121-1131 (Jun. 1994).
Kroncke et al., “Inducible Nitric Oxide Synthase in Human Diseases,” Clinical and Experimental Immunology, 113, 147-156 (1998).
Arend et al., “IL-1 Receptor Antagonist and Il-1β Production in Human Monocytes are Regulated Differently,”Journal of Immunology, 147(2), 1530-1536 (Sep. 1, 1991).
Dinarello et al., “Blocking IL-1: Interleukin 1 Receptor Antagonistin vivoandin vitro,” Immunology Today, 12(11), 404-410 (1991).
Neuner et al., “Pentoxifyllinein vivoDown-regulates the Release of IL-1β, IL-6, IL-8 and Tumour Necrosis Factor-α by Human Peripheral Blood Mononuclear Cells,”Immunology, 83(2), 262-267 (Oct. 1994).
Matsuda et al., “Establishiment of an Interleukin 6 (IL6)/B Cell Stimulatory Factor 2-Dependent Cell Line and Preparation of Anti-IL6 Monoclonal Antibodies,”European Journal of Immunology, 18, 951-956 (Jun. 1988).
Cohen et al., “CNI-1493 Inhibits Monocyte-Macrophage Tumor Necrosis Factor by Suppression of Translation Efficiency,”Proc. National Academy of Science USA, 93, 3967-3971 (Apr. 1996).
Förstermann et al., “Nitric Oxide Synthase Isozymes—Characterization, Purification, Molecular Cloning, and Functions,”Hypertension, 23(6, Part 2), 1121-1131 (Jun. 1994).
Kröncke et al., “Inducible Nitric Oxide Synthase in Human Diseases,”Clinical and Experimental Immunology, 113, 147-156 (1998).
Teun Graafland, Wim C. Nieuwpoort and Jan B. F. N. Engberts, “Steric Effects in the Intramolecular Carboxyl-Catalyzed Hydrolysis of Sulfonamides. Ab Initio Quantum Chemical Studies of the Pentacoordinated Sulfur Intermediate” inJournal of the American Chemical Society, 1981, 103, pp. 4490-4494.
Katrin Illgen, Christine Hartung, Rainer Herzschuh and Bärbel Schulze, “3-Hydroperoxy-4,5,6,7-tetrahydro-toluene-2,a-sultims: Preparation and Reactions” inMolecules, 1996, 1, pp. 139-141. (Presented Sep. 1-4, 1996).
Bärbel Schulze, Sabine Kirrbach, Katrin Illgen and Peter Fuhrmann, “Synthesis of Stable Hydroperoxides of Sultams by Oxidation of Isothiazolium Salts” inTetrahedron, 1996, vol. 52, No. 3, pp. 783-790, (Jan. 15, 1996).
Graafland, T., et al. “Structure and reactivity in intramolecular catalysis. Catalysis of sulfonamide hydrolysis by the neighboring carboxyl group”, J. Am. Chem. Soc., vol. 101, No. 23, pp. 6981-6991, (Nov. 7, 1979).
Ichikawa Takashi
Ii Masayuki
Tamura Norikazu
Crane L. E.
McKenzie Thomas C.
Takeda Pharmaceutical Company Limited
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Substituted aromatic-ring compounds, process for producing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted aromatic-ring compounds, process for producing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted aromatic-ring compounds, process for producing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3553598